Andrea Eleazar, MHS

Anbal-cel demonstrated a 67.1% complete response rate in relapsed or refractory LBCL in the phase 1/2 CRC01-01 trial, evaluating dual PD-1 and TIGIT knockdown CAR T-cell therapy.

A study of more than 205,000 patients with advanced cancer found that physician and practice factors influence clinical trial enrollment, highlighting opportunities to improve access and address participation disparities.

Patients with relapsed or refractory CTCL who responded to denileukin diftitox-cxdl experienced improvements in skin-related quality of life and overall well-being in Study 302.

The FDA grants orphan drug designation to TRX-E-002-1, an investigational small-molecule benzopyran, for the treatment of acute myeloid leukemia (AML).

The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.

Personalized ctDNA monitoring guides adjuvant therapy and flags head and neck cancer relapse months early, showing high sensitivity across HPV subtypes.

FDA priority-reviews zanubrutinib plus rituximab for untreated mantle cell lymphoma, showing 43% lower progression or death risk than bendamustine-rituximab.

Financial strain often eases after allogeneic bone marrow transplant, but persistent hardship worsens quality of life, highlighting the need for ongoing support.

FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, manufacturing controls, lot release assays, and monitoring.

Short-course neoadjuvant botensilimab plus balstilimab drives deep responses in resectable pMMR and dMMR colon cancer, with ctDNA clearance and no recurrences.

Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.

Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.

Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.

New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.

COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.

ESMO 2026 unveils GI cancer advances: targeted and immunotherapy regimens boost survival in pancreatic, colorectal, gastric, and HER2+ gastroesophageal disease.

Attending a multidisciplinary survivorship clinic before radiotherapy ended was linked to better adherence, lower recurrence risk, and improved 3-year disease-free survival in head and neck cancer.

The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.

More than 76% of US counties have no TNBC trial, and only 9.8% of rural counties have one vs 47% of metropolitan counties, a new analysis finds.

Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.

FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.

In patients 45+ with papillary thyroid cancer, men with dual BRAF V600E and TERT promoter mutations face sharply higher mortality, reshaping risk stratification.

Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.

Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.

ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.

FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.

Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.

FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary–only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.

Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.

Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.